5 ratings / 4.4 average

New Therapies for Diffuse Large B Cell Lymphoma

Zahid Bashir1,2 and Andrew John Davies3

Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease with specific subtypes and morphological variants [1]. No single genetic abnormality is diagnostic of DLBCL; however, gene-expression profiling identifies germinal center B cell-like (GCB) and activated B cell-like (ABC) as two distinct subtypes, providing important diagnostic and prognostic information (

  • Figure1
). Patients identified as having the ABC subtype have a 5-year overall survival (OS) rate of 30%, compared with an almost 60% 5-year OS rate in the GCB subgroup [2,3].

Return to top


Lymphoma and IBD: 
What is the Actual Risk?

Guillaume Pineton de Chambrun, MD1, Laurent Peyrin-Biroulet, MD2, Bénédicte De Vroey, MD1, and Jean-Frédéric Colombel, MD1
Inflammatory Bowel Disease Monitor
Targeted Therapy in Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
Alessandro M Vannucchi, MD, Lisa Pieri, MD, Elisabetta Antonioli, MD, PhD, and Paola Guglielmelli, MD, PhD
CML Leukemia and Lymphoma
Immune Reconstitution in Cord Blood Transplantation
Sameer Tulpule, FRCPath1, and Bronwen E Shaw, FRCPath, PhD1,2
CML Leukemia and Lymphoma
CML Leukemia and Lymphoma